The mechanism of action and pharmacology of talquetamab-tgvs

Talquetamab is a bispecific T cell binding antibody mainly used to treat multiple myeloma. It activates T cells by binding to the CD3 receptor expressed on the surface of T cells and to the G protein-coupled receptor class C group 5 member D (GPRC5D) on the surface of multiple myeloma cells. Through this mechanism, tarquitumab can activate the anti-tumor effect of T cells and promote the lysis of myeloma cells.

GPRC5D is a receptor expressed on the surface of multiple myeloma cells that bears some similarity to cell surface receptors on healthy keratinized epithelial cells such as skin and tongue. The bispecific design of Taquitumumab allows it to simultaneously target these cell surface receptors and promote the immune system's attack on cancer cells through interaction with T cells and tumor cells. This unique mechanism of action makes taquitumab a new drug for the treatment of multiple myeloma.

In in vitro experiments, T cells activated by Tacquitumab can induce the release of pro-inflammatory cytokines. These cytokines can enhance the immune response and further improve the anti-tumor effect. Through this mechanism, taquitumab exhibits significant antitumor activity in the treatment of multiple myeloma. In mouse models, tarquinatumumab showed good anti-tumor effects with relatively mild side effects.

Taquitumab, as an immunotherapy, exploits the natural anti-tumor function of T cells and enhances this function through the design of bispecific antibodies. Unlike traditional monospecific antibodies, Taquitumumab can act on multiple targets simultaneously, thereby improving the effectiveness of treatment. Its unique mechanism makes it an important option in the treatment of multiple myeloma, providing patients with new treatment hope.

Reference materials:https://www.talveyhcp.com/